|
 The trials evaluated the effect of veliparib, in combination with a
chemotherapy regimen, on patients with non-small cell lung cancer (NSCLC)
and triple-negative breast cancer.
In one trial, the combination treatment failed to improve the
overall survival of NSCLC patients, who had smoked within the past
12 months and had more than 100 smoking events in their lifetime.
In another trial, which evaluated the treatment on patients with
early-stage triple-negative breast cancer, the drug did not achieve
the complete pathologic response.
Veliparib belongs to a closely watched class of new medicines called
PARP inhibitors, which block enzymes involved in repairing damaged
DNA, thereby helping to kill cancer cells.
The only approved drugs in the class include AstraZeneca Plc's
Lynparza, also known as olaparib, and Tesaro Inc's niraparib.
Tesaro's niraparib won the U.S. Food and Drug Administration's
approval for the treatment of recurrent ovarian cancer late in March
this year.
[to top of second column] |
Other experimental PARP inhibitors include Clovis Oncology Inc's
rucaparib and Pfizer Inc's talazoparib.
Abbvie's shares were marginally down after the bell on Wednesday.
(Reporting by Divya Grover in Bengaluru; Editing by Savio D'Souza
and Bill Rigby)
[© 2017 Thomson Reuters. All rights
reserved.] Copyright 2017 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
